Predictive Technology Group, Inc. Entered into Strategic Development Agreement with Nebula Genomics
June 21, 2021 at 05:15 pm
Share
Predictive Technology Group, Inc. announced that on May 7, 2021, the company entered into a strategic development agreement (the "Agreement") with Nebula Genomics ("Nebula"). Under the terms of the Agreement, the company may offer Nebula products to its customers, including 30x whole genome sequencing testing, analytical tools, and other products and services, which are fulfilled by Nebula. The Agreement includes a revenue sharing arrangement between the company and Nebula. Nebula has agreed to provide the company with technologies and services to assist in Direct-To-Consumer ("DTC")
and clinical diagnostic markets including privacy technologies, such as blockchain, and analytical tools. The company and Nebula intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. These development activities are expected to be governed by joint scientific and medical advisory boards with representation from both companies.
Predictive Technology Group, Inc. is a life science company. The Company, through its subsidiaries, is focused on specific points of the care continuum, including detection, prevention and treatment. Predictive Analytics, Predictive Laboratories, and Predictive Biotech each bring critical solutions to personalized patient care by leveraging its research, genomics, genetic library and expertise in developing bioscience solutions. Predictive Analytics is the repository for its genetic library. Predictive Biotech provides regenerative medicine. Its products are derived from tissue sources rich in properties that support the bodyâs natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Its research and use of processing methods has propelled its placental-derived and Whartonâs Jelly umbilical cord-derived products to new heights.